Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Minerva Neurosciences, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.68 · Expires 2036-06-02 | Direct | 50,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 22:00 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001642053-26-000002 · form4-06052026_060607.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:15 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001642053-25-000004 · form4-12232025_041211.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-12-21 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following December 22, 2025 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 22:45 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001415889-24-028542 · form4-12062024_051210.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-12-04 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following December 5, 2024 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 12:58 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-23-050825 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-09-26 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 28, 2022 23:33 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-22-039684 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2032-06-09 F1 · security: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2 · derivative.exercise_price: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. F2 · derivative.underlying_shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · balance_after: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:37 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | SaleCommon Stock | 55,635 | $0.88 | $48,958.80 |
DisclosureSEC source: 0001209191-21-067938 · doc4.xml · nonDerivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,553 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9235 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:40 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-21-040673 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2021 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 21:00 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-20-036337 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2020 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 20:26 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 10,000 | $5.55 | $55,500.00 |
DisclosureSEC source: 0001209191-19-039266 · doc4.xml · nonDerivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,188 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.52 to $5.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 31, 2019 Filed May 31, 2019 21:41 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-19-033705 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following May 31, 2019 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:37 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.25 | $0.00 |
DisclosureSEC source: 0001209191-18-036979 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 7, 2018 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:41 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037756 · doc4.xml · derivative · entry 1 Kupfer David · CIK 0001642053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 1, 2017 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.